News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vivaldi Biosciences Inc. Acquires Clinical-Stage Influenza Vaccine Assets


10/10/2013 9:59:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FORT COLLINS, Colo.--(BUSINESS WIRE)--Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company developing live attenuated influenza vaccines (LAIVs) against pandemic and seasonal influenza, today announced that it has acquired from Baxter Healthcare SA (Glattpark, Switzerland) research and development assets, including intellectual property, clinical data, know-how and materials, for LAIVs in which the gene for influenza nonstructural protein 1 (NS1) has been fully deleted. These assets previously were owned by AVIR Green Hills Biotechnology AG (Vienna, Austria).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES